Neutral
Johnson & Johnson's stock drops 1.6% amid analyst target increases and pipeline updates
In the past 24 hours, Johnson & Johnson's (JNJ) stock declined by 1.6% to approximately $267.66. This movement occurred despite recent analyst target increases and positive developments in the company's drug pipeline. Notably, Bank of America raised its price target to $278 from $263, and JPMorgan increased its target to $285 from $270. Additionally, new data on the IMAAVY drug for generalized myasthenia gravis and positive results for Tremfya and Caplyta have been reported. However, concerns about potential third-quarter earnings falling below expectations and ongoing litigation costs may be contributing to the stock's recent performance.
Key points
- Bank of America raises JNJ price target to $278, citing increased confidence in Icotyde's commercial potential.
- JPMorgan increases JNJ price target to $285, maintaining a Neutral rating ahead of the earnings report on October 13.
- New IMAAVY data shows sustained disease control and improved daily function in generalized myasthenia gravis patients.
- Concerns about potential third-quarter earnings falling below expectations and ongoing litigation costs may impact JNJ's stock performance.
Sources
- Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.6% - Here's WhyMarketBeat · October 8, 2026
- Johnson & Johnson (JNJ) Stock News & UpdatesStockTitan · October 2, 2026
- Johnson & Johnson (VIE:JNJ) Stock Price & OverviewStockAnalysis · October 8, 2026
- Johnson & Johnson (TSX:JNJ) Stock Price & OverviewStockAnalysis · October 8, 2026
AI-generated from public news sources. Not financial advice.
